19 Recruiting Studies Using Cobimetinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Cobimetinib
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
📍 University of Colorado Cancer Center — Aurora, Colorado
Cancer
View Study & Checklist ➔Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Breast Inflammatory Carcinoma
View Study & Checklist ➔Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Metastatic Thyroid Gland Carcinoma
View Study & Checklist ➔Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
BRAF V600E Mutation Present
View Study & Checklist ➔A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
📍 California Pacific Medical Center Research Institute — San Francisco, California
Melanoma
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
📍 UCSF Helen Diller Family CCC — San Francisco, California
Ovarian Cancer
View Study & Checklist ➔A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
📍 UC Davis — Sacramento, California
Non-Small Cell Lung Cancer
View Study & Checklist ➔Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
📍 M D Anderson Cancer Center — Houston, Texas
BRAF V600 Wild Type
View Study & Checklist ➔XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Melanoma
View Study & Checklist ➔Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
📍 Oregon Health and Science University — Portland, Oregon
Chronic Myelomonocytic Leukemia (CMML)
View Study & Checklist ➔Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Advanced Endometrial Carcinoma
View Study & Checklist ➔Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Metastatic Distal Bile Duct Adenocarcinoma
View Study & Checklist ➔A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
📍 Massachusetts general Hospital — Boston, Massachusetts
Non-small Cell Lung Cancer
View Study & Checklist ➔Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Metastatic Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
📍 City of Hope Medical Center — Duarte, California
Thyroid Gland Follicular Carcinoma
View Study & Checklist ➔A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Non-small Cell Lung Cancer
View Study & Checklist ➔Targeted Pathway Inhibition in Patients With Pancreatic Cancer
📍 OHSU Knight Cancer Institute — Portland, Oregon
Locally Advanced Pancreatic Ductal Adenocarcinoma
View Study & Checklist ➔Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
📍 Phoenix Children's Hospital — Phoenix, Arizona
Langerhan's Cell Histiocytosis
View Study & Checklist ➔Using Tumor Models to Determine Treatments
📍 Princess Margaret Cancer Centre — Toronto, Ontario
Pancreatic Ductal Carcinoma
View Study & Checklist ➔